Key result
Urotensin II plays a major role in the pathophysiology of cardiovascular diseases, making its receptor a potential target for pharmacotherapy using synthetic urotensin blockers.
Urotensin II is a potent vasoconstrictor that plays a major role in cardiovascular pathophysiology, making its receptor a potential target for pharmacotherapy.
Should not yet alter practice; leaves open whether urotensin receptor blockade will prove clinically effective.
Urotensin II was first identified over 30 years ago as a potent vasoconstrictor, and the identification of its receptor in the heart, lungs, blood vessels, and brain have made it a potential target for human pharmacotherapy. Current research would suggest that urotensin II plays a major role in the pathophysiology of various cardiovascular disease entities. This article discusses the biologic effects of urotensin under normal and pathophysiologic conditions, and reviews the research experiences with synthetic urotensin blockers in the treatment of various cardiovascular illnesses.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2008) conducted a review in Cardiovascular illnesses. Synthetic urotensin blockers was evaluated. Urotensin II plays a major role in the pathophysiology of cardiovascular diseases, making its receptor a potential target for pharmacotherapy using synthetic urotensin blockers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: